GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Arcadia Biosciences Inc (NAS:RKDA) » Definitions » Long-Term Debt & Capital Lease Obligation

Arcadia Biosciences (Arcadia Biosciences) Long-Term Debt & Capital Lease Obligation : $0.16 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Arcadia Biosciences Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Arcadia Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.16 Mil.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. Arcadia Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.16 Mil. Arcadia Biosciences's Total Assets for the quarter that ended in Dec. 2023 was $19.71 Mil. Arcadia Biosciences's LT-Debt-to-Total-Asset for the quarter that ended in Dec. 2023 was 0.01.

Arcadia Biosciences's LT-Debt-to-Total-Asset declined from Dec. 2022 (0.04) to Dec. 2023 (0.01). It may suggest that Arcadia Biosciences is progressively becoming less dependent on debt to grow their business.


Arcadia Biosciences Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Arcadia Biosciences's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcadia Biosciences Long-Term Debt & Capital Lease Obligation Chart

Arcadia Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.60 7.49 2.22 1.01 0.16

Arcadia Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 0.76 0.53 0.35 0.16

Arcadia Biosciences Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


Arcadia Biosciences  (NAS:RKDA) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Arcadia Biosciences's LT-Debt-to-Total-Asset ratio for the quarter that ended in Dec. 2023 is calculated as:

LT-Debt-to-Total-Asset (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0.155/19.705
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


Arcadia Biosciences Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Arcadia Biosciences's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcadia Biosciences (Arcadia Biosciences) Business Description

Traded in Other Exchanges
Address
5950 Sherry Lane, Suite 215, Dallas, TX, USA, 75225
Arcadia Biosciences Inc is a producer and marketer of innovative, plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements primarily in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water, ProVault topical pain relief, and SoulSpring bath and body care.
Executives
Thomas J. Schaefer officer: Chief Financial Officer 202 COUSTEAU PLACE STE 105, DAVIS CA 95618
Stanley Jr Jacot officer: Chief Executive Officer 202 COUSTEAU PLACE STE 105, DAVIS CA 95618
Pamela Haley officer: Chief Financial Officer 202 COUSTEAU PLACE, DAVIS CA 95618
Laura Pitlik officer: Chief Marketing Officer 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Chris Cuvelier officer: Chief Growth Officer 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Deborah D Carosella director 3603 HAVEN AVE, SUITE E, MENLO PARK CA 94025
Matthew T Plavan officer: Chief Financial Officer C/O THERMOGENESIS CORP., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Randall Shultz officer: Chief Technology Officer 4222 E. THOMAS ROAD, SUITE 320, PHOEBIIX AZ 85018
Sarah Reiter officer: Chief Commercial Officer 202 COUSTEAU PLACE, DAVIS CA 95618
Lilian Shackelford Murray director 228 BEACH ROAD, BELVEDERE CA 94920
Kevin Comcowich director C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
Eric J. Rey director, officer: President and CEO ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Zhongjin Lu officer: VP Product Development ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Amy Yoder director C/O SPECTRUM BRANDS, INC., 6 CONCOURSE PARKWAY, SUITE 3300, ATLANTA GA 30328